Orthogon Therapeutics, a Canton, MA-based developer of novel antiviral medicines, raised $5.2M in funding.
Backers were not disclosed.
The company intends to use the funds to accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients.
Led by Ali H. Munawar, Ph.D., CEO, Orthogon Therapeutics provides a therapeutic strategy that offers a solution to managing the full BK virus risk ladder, from early reactivation, indicated by virus shedding in the urine, to systemic spread and severe complications such as BKVAN, graft dysfunction, and transplant failure. By intervening at the earliest stages of reactivation, this approach extends treatment benefits to more patients, reduces the need for aggressive late-stage interventions, and improves long-term transplant success.
The company has developed small molecule drugs that directly target viral proteins essential to the polyomavirus life cycle. Polyomaviruses lack conventional antiviral protein targets and have eluded drug development for decades.
FinSMEs
10/12/2024